Neurofilament light chain (NFL) levels reflect axonal damage in different inflammatory and neurodegenerative central nervous system conditions, in correlation with disease severity. Our aim was to determine the possible diagnostic and prognostic value of serum and cerebrospinal fluid (CSF) NFL levels in subjects with different forms of acquired peripheral neuropathies (PN).
| INTRODUCTION
Neurofilament light (NFL) protein has been recently evaluated as a diagnostic and prognostic biomarker of several neurodegenerative and inflammatory central nervous system (CNS) conditions. [1] [2] [3] The high correlation between serum and cerebrospinal fluid (CSF) NFL values with disease activity supports a key role of NFL in monitoring tissue damage and treatment effects. [4] [5] [6] Up to now, only two studies analysed serum NFL values in subjects with peripheral nervous system (PNS) diseases, and in particular in patients with vasculitic neuropathy 7 and inherited peripheral neuropathies (PN). 8 We studied cases with different acquired PN and compared serum/CSF NFL levels with clinical data, neurophysiological findings, and final outcome in order to investigate the utility of NFL as a diagnostic and prognostic biomarker in acquired PNS disorders.
| METHODS

| Study subjects
We studied 25 patients with well-defined acquired PN consecutively referred to our Neurology unit. Demographic and clinical data including time from onset, disease severity measured using the overall neuropathy limitations scale (ONLS) at sampling, 9 treatment, and clinical evaluation at last follow-up were collected ( Table 1 ). The final diagnosis was defined according to five diagnostic categories: (1) Guillain-Barré syndrome (GBS), (2) 
| Neurophysiological study
All patients underwent nerve conduction studies to confirm and characterise PNS involvement. The main pattern (axonal, demyelinating, mixed axonal-demyelinating), the presence of conduction blocks and F waves were analysed in each case with a standard neurophysiological examination performed within 1 month of CSF/serum sampling. Slowing conduction velocity was considered suggestive of demyelination, while a reduction of potential amplitude was indicative of axonal loss.
| Laboratory data
For each examined subject paired serum and CSF samples were obtained. Protein content, IgG index, and oligoclonal bands (OBs)
were analysed according to the international guidelines.
| NFL analysis
Paired CSF and serum samples were centrifuged at room temperature, aliquoted in polypropylene tubes within 1 hour of collection, and then stored at −80 C. The concentration of NFL protein was determined in duplicates by investigators blinded to clinical data using a HD-1 immunoassay analyzer, Quanterix, Simoa, Lexington, MA, USA, which runs ultra-sensitive paramagnetic bead-based enzyme-linked immunosorbent assays.
| Statistical analyses
A rank-based non-parametric test (Mann-Whitney test) was used to differentiate PN and controls. Pearson correlation analysis was applied to test the correlation between clinical and CSF/serum data. Statistical analysis was performed using PRISM 6 (GraphPad Software analysis, La Jolla, CA, USA).
| RESULTS
The Figure 1A ,B, respectively). NFL values were higher (fold change 44.6) in the CSF (median: 1407 pg/mL, range: 140.2-12 661) than in serum. A significant correlation (r = 0.71, P ≤ 0.01) between NFL levels in the CSF and serum was observed only in subjects with possible signs of BNB damage ( Figure S1 , Supporting Information).
The association between NFL values, sex, and age was not statistically significant. A significant correlation was noted between serum NFL 
| DISCUSSION
Although we studied only a small patient population, we here provide preliminary data on the increase of serum NFL protein levels in patients with different forms of acquired PN, extending previously reported findings on inherited PN and vasculitic neuropathies. 7, 8 According to our data, NFL levels are increased also in the CSF of patients with different acquired PN, a finding previously noted only . NFL values were expressed in pg/mL. ** P < 0.01; *** P < 0.001. Abbreviations: CIDP, chronic inflammatory demyelinating polyneuropathy; GBS, Guillain-Barré syndrome; LSS, Lewis Sumner syndrome; MAG, myelin-associated glycoprotein; MMN, multifocal motor neuropathy; NFL, neurofilament light chain; ONLS, overall neuropathy limitations scale; PN, peripheral neuropathies in subjects with CNS disorders [2] [3] [4] 6 and GBS in a single report. 10 These data suggest that serum and CSF NFL levels could reflect an ongoing axonal damage in both CNS and PNS conditions. PNS involvement, reflected by NFL levels, does not depend on the main PN pattern, because no differences were noted according to neurophysiological findings. Our observations confirm previous data on inherited PN, were no differences of plasma NFL levels were noted among patients with axonal and demyelinating forms of CharcotMarie tooth disease. These findings seem to reflect the prominent axonal loss in PN disorders, as previously suggested in inherited conditions. 8 Moreover, in our cohort, different final diagnoses did not influence serum/CSF NFL values, suggesting the possible use of this biomarker in PNS disorders, independently on the clinical subtypes.
Interestingly, we noticed a correlation between CSF and serum NFL levels only in subjects with a possible BNB damage, supporting the idea that disrupted BNB could contribute early in the inside-out transport of inflammatory mediators and biomarkers of neurodegeneration. Biomarkers that enable the identification of BNB dysfunction are not well established, and only pathological examinations or radiological studies seem reliable methods to assess BNB derangements. However, we assume that an increase of protein content/IgG index or the presence of OBs might be indicative of BNB in patients with peripheral neuropathy, in accordance with previous reports. 10 We also demonstrate that serum NFL levels and not CSF ones correlate with disease activity at sampling, and might predict subsequent progression of disability. These data suggest that serum NFL levels might be more reliable than CSF ones for monitoring disease activity and tissue damage in PNS conditions. Differences in the mechanisms of release and/or clearance of NFL into blood and CSF in CNS and PNS diseases and the predominant expression of NFL in largecaliber myelinated axons and in the post-synaptic terminal might partially explain the lack of association between clinical findings and CSF NFL levels in our cohort. The heterogeneous population included in our study and the short follow-up available in patients with acute neuropathies might also explain this discrepancy with the previous single observation that CSF NFL in the acute stage of GBS seems to predict long-term outcome. 11 In conclusion, we present initial data suggesting that serum NFL levels might reflect neuroinflammation-mediated axonal injury in acquired PN, independently of the final diagnosis and pathogenesis. The main limitation of our study is the small sample size. Future extensive and prospective studies with larger cohorts of patients with PN and repeated determinations in individual cases combined with better analysis of inflammatory profiling are mandatory. These data might confirm the role of serum NFL levels as predictors of disease progression and treatment response also in PNS conditions.
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